Status:
WITHDRAWN
Corneal Versus Conjunctival Delivery Using a Delivery Device
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Compare the antihypertensive efficacy of three methods for installing Xalatan
Eligibility Criteria
Inclusion
- Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes
Exclusion
- History of closed/barely open anterior chamber angle or a history of angle closure
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00143429
Last Update
February 2 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.